Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
P/E ratio for Insulet Corporation (PODD)
P/E ratio as of 2023: 73.36
According to Insulet Corporation's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 73.36. At the end of 2022 the company had a P/E ratio of 4439.85.
P/E ratio history for Insulet Corporation from 2002 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 73.36 |
| 2022 | 4439.85 |
| 2021 | 1072.17 |
| 2020 | 2433.56 |
| 2019 | 894.28 |
| 2018 | 1418.22 |
| 2017 | -149.16 |
| 2016 | -73.96 |
| 2015 | -29.20 |
| 2014 | -49.75 |
| 2013 | -44.55 |
| 2012 | -19.61 |
| 2011 | -15.38 |
| 2010 | -10.04 |
| 2009 | -5.34 |
| 2008 | -2.30 |
| 2007 | -7.32 |
| 2006 | -0.16 |
| 2005 | -0.22 |
| 2004 | -0.34 |
| 2003 | -0.36 |
| 2002 | -0.38 |